tradingkey.logo
tradingkey.logo
Suchen

Ginkgo Bioworks Holdings Inc

DNA
Zur Watchlist hinzufügen
10.400USD
+0.110+1.07%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
605.36MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Ginkgo Bioworks Holdings Inc Unternehmen

Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.

Ginkgo Bioworks Holdings Inc Informationen

BörsenkürzelDNA
Name des UnternehmensGinkgo Bioworks Holdings Inc
IPO-datumApr 19, 2021
CEOKelly (Jason)
Anzahl der mitarbeiter834
WertpapierartOrdinary Share
GeschäftsjahresendeApr 19
Addresse27 Drydock Avenue
StadtBOSTON
BörseNASDAQ OMX NASDAQ Basic NYSE
LandUnited States of America
Postleitzahl02210
Telefon18774425362
Websitehttps://investors.ginkgobioworks.com/
BörsenkürzelDNA
IPO-datumApr 19, 2021
CEOKelly (Jason)

Führungskräfte von Ginkgo Bioworks Holdings Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Harry Evans Sloan, J.D.
Mr. Harry Evans Sloan, J.D.
Independent Director
Independent Director
271.42K
-3.99%
Shyam Sankar
Shyam Sankar
Independent Chairman of the Board
Independent Chairman of the Board
72.37K
-14.95%
Dr. Kathy Hopinkah Hannan
Dr. Kathy Hopinkah Hannan
Independent Director
Independent Director
25.82K
+41.91%
Mr. Christian O. Henry
Mr. Christian O. Henry
Independent Director
Independent Director
24.31K
-44.52%
Dr. Sri Kosuri
Dr. Sri Kosuri
Independent Director
Independent Director
24.07K
-100.00%
Mr. Ross Fubini
Mr. Ross Fubini
Independent Director
Independent Director
10.82K
-100.00%
Dr. Jason Kelly
Dr. Jason Kelly
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Reshma Shetty
Dr. Reshma Shetty
President, Chief Operating Officer, Director
President, Chief Operating Officer, Director
--
--
Mr. Steven P. (Steve) Coen, CPA
Mr. Steven P. (Steve) Coen, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Harry Evans Sloan, J.D.
Mr. Harry Evans Sloan, J.D.
Independent Director
Independent Director
271.42K
-3.99%
Shyam Sankar
Shyam Sankar
Independent Chairman of the Board
Independent Chairman of the Board
72.37K
-14.95%
Dr. Kathy Hopinkah Hannan
Dr. Kathy Hopinkah Hannan
Independent Director
Independent Director
25.82K
+41.91%
Mr. Christian O. Henry
Mr. Christian O. Henry
Independent Director
Independent Director
24.31K
-44.52%
Dr. Sri Kosuri
Dr. Sri Kosuri
Independent Director
Independent Director
24.07K
-100.00%
Mr. Ross Fubini
Mr. Ross Fubini
Independent Director
Independent Director
10.82K
-100.00%

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Ginkgo Bioworks Holdings Inc?

Die fünf größten Anteilseigner von Ginkgo Bioworks Holdings Inc sind: Mr. Harry Evans Sloan, J.D.

Wie viele Institutionen halten Anteile an Ginkgo Bioworks Holdings Inc (DNA)?

Mit Stand vom 2026Q1 halten 597 Institutionen Anteile an Ginkgo Bioworks Holdings Inc, mit einem Gesamtmarktwert von etwa 33.44M, was 62.67% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -4844240.00 gestiegen.